机构:[a]Department of Neurology, Xuan Wu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China神经内科首都医科大学宣武医院[b]Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences and Peking Union Medical College, China[c]Beijing Institute of Geriatrics, Xuan Wu Hospital, Capital Medical University, China老年医学科首都医科大学宣武医院
Ginsenoside Rg1 (Rg1) is a pharmaceutically active component of ginseng, and is neuroprotective as reported. This experiment investigated whether Rg1 is effective on injury or apoptosis of Chinese hamster ovary (CHO) cells as induced by A beta(25-35), or by excessive A beta(1-42) and the mechanism involved. We used different Rg1 doses to pretreat CHO cells stably expressing APP751 and either wild-type PS1 (WT) or mutant PS1 (M146L) for 24 h. Cell viability and apoptosis were examined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction assay, terminal deoxynucleotidyl-transferase-mediated dUTP transferase nick-end labeling (TUNEL), and fluorescent annexin V/propidium iodide (Annexin V-FITC/PI) staining. The expression of A beta(1-42) and caspase-3 was investigated with immunofluorescent staining. Our results reveal that pretreatment with 25 mu M Rg1 can improve viability in cells injured by A beta(25-35), inhibit the intracellular A beta(1-42)-induced apoptosis in mutant PSI M146L cells, and reduce the levels of A beta(1-42) and active caspase-3. This study demonstrated that Rg1 can reduce the production of A beta(1-42) and the activation of caspase-3, as a result, to attenuate the cell apoptosis. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
基金:
the China Postdoctoral Science Foundation (Grant 2005037382), National Key Technology R&D Program in the Eleventh Five-year Plan Period (2006BAI02B01),
the National Basic Research 973 Program (2006CB500700), Beijing Natural Science Foundation (7071004),
and Funding Project for Academic Human Resources Development in Institutions of Higher Learning Under the Jurisdiction of Beijing Municipality.